PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
Oct 11, 2022 · Business Wire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and...
PsychoGenics Appoints Mark A. Varney, PhD as Chief Scientific Officer
PARAMUS, N.J., November 4, 2019 – PsychoGenics Inc., announced the appointment of Mark A. Varney, Ph.D., as Chief Scientific Officer...
In Vivo AI Platforms
PsychoGenics’ Cube Technologies: RevolutionizingNeuropsychiatric Drug Discovery CNS disorders impact hundreds of millions of patients who not only suffer from severely...
News
Stay up to date on PsychoGenics and the world of preclinical drug discovery.
eCube® In Vivo AI Platform for EEG-Based Drug and Biomarker Discovery
Advancing AI-Assisted Drug Discovery with the Translational Power of EEG eCube® is a pharmaco-EEG platform that collects data from novel...
PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
April 6, 2023・Businesswire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO...
PsychoGenics CEO Explores CNS Drug Development Trends
February 4, 2023 · By Brian Buntz · Drug Discovery & Development In the late 2000s, many companies, particularly Big...
PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP)
PARAMUS, N.J., November 6, 2019 – PGI Holding Corporation (PsychoGenics) announced that it has been awarded an Indefinite Delivery Indefinite...
Why Psychogenics and Emyria are Collaborating to Examine MDMA-Inspired Compounds
By Brian Buntz · Oct 12, 2022 · Drug Discovery & Development CNS-focused contract research organization PsychoGenics has forged a collaboration with clinical-stage...
PsychoGenics Launches Updated Corporate Identity and Brand
PsychoGenics, Inc. (“PsychoGenics” or the “Company”), the leading contract research organization (CRO) specializing in the central nervous system (CNS) focused preclinical and translational drug discovery services, is proud to unveil its refreshed corporate identity and brand.